A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs TAK 063 (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Takeda
- 22 Sep 2016 Status changed from recruiting to completed.
- 18 Aug 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 26 Jun 2015 New trial record